Work

Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.4065

Authors: Karina Kulangara, Lindsay Guerrero, Alex Posch, Scott Boyer, Debra Ann Hanks, Josette Carnahan, Jiangdian Wang, Jared Lunceford, Mary Savage, Matthew John Marton, Scott K. Pruitt, Jonathan Wes Juco, Kenneth Emancipator

Institutions: Agilent Technologies (United States), Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890639320

Cites:

Cited by: 23

Related to: 10